4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial

Summary by AI BETAClose X

4basebio PLC has secured a significant Clinical Supply Agreement with a leading cancer immunotherapy innovator to provide GMP-grade opDNA® starting material for a Phase II clinical trial, which is projected to generate a seven-figure revenue stream over the next twelve months. This agreement highlights 4basebio's capability to supply synthetic DNA as a crucial component for the client's immunotherapy candidate, offering a safer and more cost-effective alternative to plasmid DNA by eliminating microbial contamination and antibiotic resistance genes, thereby potentially accelerating therapeutic development timelines.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings